Hundreds of family planning clinics that lost their Title X federal grants and 340B eligibility because they opposed a Trump-era rule barring them from providing abortion referrals might return to Title X and 340B soon.
The U.S. Department of Health
…
A federal district judge has given government lawyers until Wednesday to weigh in on drug manufacturer Sanofi’s request for emergency protection from being brought before a 340B administrative dispute resolution panel.
U.S. Chief District Judge Freda Wolfson gave the U.S.
…
The U.S. Centers for Medicare & Medicaid Services (CMS) final rule that will set what Medicare will pay 340B hospitals for physician-administered drugs next year is another step closer to release.
CMS last week Thursday sent its calendar year
…
Researchers who reported in 2018 that the 340B program leads to hospital-physician practice consolidation but probably not to better care or outcomes for low-income patients have released a new 340B study, this time on hospital provision of uncompensated care. The
…SPONSORED CONTENT
When it comes to operating a 340B program, health systems, hospitals, and other entities that participate in the federal drug pricing program administered by HRSA have found that hiring graduates of the Apexus Advanced 340B Operations Certificate Program is helping them achieve compliance and implement a successful 340B program.
In the
…
Pharmaceutical industry vendor Kalderos has asked a federal court to vacate a federal health agency’s policy prohibiting drug manufacturers from conditioning 340B drug discounts on covered entities’ submission of drug claims data.
Kalderos has created a service called 340B
…
Drug manufacturer Sanofi yesterday asked a federal judge in New Jersey to stay 340B administrative dispute resolution (ADR) proceedings against it brought by health centers seeking to overturn Sanofi’s restrictions on 340B pricing when covered entities use contract pharmacies.
Sanofi
…
The U.S. Health Resources and Services Administration (HRSA) told 340B Report yesterday in response to an inquiry that 340B program administrative dispute resolution (ADR) panels have been assigned—signaling that an unknown number of proceedings might begin on ADR petitions by
…
Drug manufacturer Boehringer Ingelheim on Tuesday disputed a federal health agency’s finding a day earlier that BI’s denials of 340B discounts on its drugs when hospitals use contract pharmacies are illegal.
“Boehringer Ingelheim Pharmaceuticals, Inc. is committed to ensuring that its
…
A federal district judge in Rochester, N.Y., has given four insulin and diabetes drug manufacturers until Oct. 29 to file a motion to dismiss an upstate New York health center’s lawsuit claiming the manufacturers conspired to stop offering 340B pricing
…
×
*Sign up for news summaries and alerts from 340B Report
